Article

Verteporfin launched into Japanese market

New York-Japanese patients have access to the only treatment for some forms of wet age-related macular degeneration (AMD) with the launch of verteporfin (Visudyne, QLT PhotoTherapeutics/Novartis Ophthalmics) in Japan.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
ViaLase, John A. Moran Eye Center unveil research partnership to spark glaucoma research, innovation
December 11th 2024

ViaLase, John A. Moran Eye Center unveil research partnership to spark glaucoma research, innovation

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Nona Biosciences and Kodiak Sciences partner to develop novel antibodies for ophthalmic diseases
December 10th 2024

Nona Biosciences and Kodiak Sciences partner to develop novel antibodies for ophthalmic diseases

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Diagnostic Maze: Navigating the complexity of isolated optic disc edema in syphilitic uveitis
December 10th 2024

Diagnostic Maze: Navigating the complexity of isolated optic disc edema in syphilitic uveitis

New study highlights retinopathy risk from hair dye use
December 9th 2024

New study highlights retinopathy risk from hair dye use

© 2024 MJH Life Sciences

All rights reserved.